Centre National De La Recherche Scientifique

Institut Pasteur

Institut Curie

Other

Institut National De La Sante Et De La Recherche Medicale

Institu Curie

Daniel Louvard

Sylvie Robine

Monique Arpin

Alphonse Garcia

Eric Pringault

Andre Choulika

Charles Babinet

Brigitte Dudouet

Michel Cohen-Tannoudji

Frederic Jaisser

Manuel Buchwald

Tiziana Crepaldi

Marie-Alyette Costa De Beauregard

Daniel Pinto

Alexandre Edelman

Dominique Chesnoy-Marchais

Ming Chen

Alexis Gautreau

Roy M Golsteyn

Evelyne Friederich

Cecile Sykes

Jacques Prost

Vincent Noireaux

Frédéric Jaisser

The invention relates to regulatory sequences of the mouse villin gene that efficiently drive transgenic expression in immature and differentiated epithelial cells of the intestine and uro-genital tracts. The invention also relates to recombinant constructs comprising said regulatory sequences, for the control of the targeted expression of determined nucleic acid sequences so-called (heterologous sequences or also transgenes), in cells or tissues originating from the intestinal mucosa. A further object of the invention is to provide cells, tissues or organisms including animals, expressing said determined nucleic acid sequences in a targeted manner.

Regulatory sequences of the mouse villin gene&#x2014;use in transgenesis

The invention concerns peptide fragments of the WASP family proteins, or peptides derived from said fragments, and their uses in particular for preparing reagents for use in implementing a method for detecting or screening molecules with inhibiting or stimulating effect on the formation of the actin cytoskeleton, hence an inhibiting or stimulating effect on cellular motility.

Wasp family protein fragments, and use thereof

The invention relates to methods of introducing a heterologous DNA sequence into a mouse embryonic stem cell wherein the DNA sequence is inserted by homologous recombination into a villin gene/I-SceI hybrid by creating a double strand break with I-SceI meganuclease. Subsequently, the mouse embryonic stem cells can be used to generate a transgenic mouse comprising the heterologous DNA sequence. Additionally, the methods can be used for gene replacement in ovo where a mouse oocyte containing a villin gene/I-SceI hybrid within its genome exists or is first generated. More generally, the methods can be used for the targeted insertion of a heterologous DNA sequence into any cell containing a villin gene/I-SceI hybrid sequence within its genome.

I-Sce I induced gene replacement and gene conversion in embryonic stem cells

The invention relates to a pharmaceutical composition containing an effective amount of ezrin mutated on tyrosine 353, or a functional fragment or derivative thereof, in association with a pharmaceutically acceptable carrier, for use preferably in the prevention and/or treatment of tumors.

Pharmaceutical composition containing ezrin mutated on tyrosine 353

The invention relates to a recombinant nucleic acid, characterized in that it comprises:

Stable cell lines expressing the CFTR protein or a mutant of this

This invention relates to a method of constructing a villin gene hybrid by inserting an I-Sce I restriction site next to or within a gene or cDNA encoding a villin protein. The insertion site of the I-Sce I restriction site is chosen as to provide a first downstream part and a second upstream part from the site, containing at least twelve nucleotides of the gene or cDNA encoding the villin protein. Furthermore, the insertion of the restriction permits a high frequency of homologous recombination events. The villin gene hybrid may be used to transfect eukaryotic cells, and particularly, embryonic stem cells.

I Sce I-induced gene replacement and gene conversion in embryonic stem

The invention relates to nucleic acid fragments characterized in that they comprise from 8 to 40 nucleotides and in that their sequence is contained either in the DNA coding sequence of the gene for human villin or in any DNA fragment exactly complementary to one of the former and hence containing the same number of deoxynucleotides, or any corresponding RNA fragment containing the same number of ribonucleotides. The invention also relates to the application of these fragments to a procedure for the in vitro detection of the presence of a nucleic acid characteristic of human villin.

Specific nucleic acid fragments of the gene for human villin-their use

Antibodies, both polyclonal and monoclonal, recognize and bind human villin. Hybridomas, producing monoclonal antibodies which bind human villin, are also provided.

Antibodies which recognize and bind human villin

In vitro diagnosis of malignant cells originating in the digestive tract by placing a biological specimen in contact with a reagent recognizing the gene coding for human villin.

Agents for the in vitro diagnosis of malignant cells originating in the

Growing community of inventors

Sceaux, France

Daniel Louvard